Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Johnson and Johnson
Colorcon
Mallinckrodt
Express Scripts

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Sun Pharm Industries Company Profile

See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for SUN PHARM INDUSTRIES, and when can generic versions of SUN PHARM INDUSTRIES drugs launch?

SUN PHARM INDUSTRIES has one hundred and sixty-seven approved drugs.

There is one US patent protecting SUN PHARM INDUSTRIES drugs.

There are twenty patent family members on SUN PHARM INDUSTRIES drugs in seventeen countries and one hundred and two supplementary protection certificates in fifteen countries.

Summary for Sun Pharm Industries
International Patents:20
US Patents:1
Tradenames:100
Ingredients:97
NDAs:167

Drugs and US Patents for Sun Pharm Industries

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Industries METOCLOPRAMIDE HYDROCHLORIDE metoclopramide hydrochloride TABLET;ORAL 071536-001 Apr 28, 1993 DISCN No No   Start Trial   Start Trial
Sun Pharm Industries RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE hydralazine hydrochloride; hydrochlorothiazide; reserpine TABLET;ORAL 088570-001 Apr 10, 1984 DISCN No No   Start Trial   Start Trial
Sun Pharm Industries DEXAMETHASONE dexamethasone TABLET;ORAL 084765-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Sun Pharm Industries SOTALOL HYDROCHLORIDE sotalol hydrochloride TABLET;ORAL 075515-001 Oct 15, 2001 DISCN No No   Start Trial   Start Trial
Sun Pharm Industries MORPHINE SULFATE morphine sulfate TABLET, EXTENDED RELEASE;ORAL 205634-001 Aug 25, 2016 AB RX No No   Start Trial   Start Trial
Sun Pharm Industries NALIDIXIC ACID nalidixic acid TABLET;ORAL 070270-001 Jun 29, 1988 DISCN No No   Start Trial   Start Trial
Sun Pharm Industries BUTALBITAL, ACETAMINOPHEN AND CAFFEINE acetaminophen; butalbital; caffeine TABLET;ORAL 040601-001 Jul 29, 2005 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Sun Pharm Industries

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Industries BACTRIM sulfamethoxazole; trimethoprim SUSPENSION;ORAL 017560-001 Approved Prior to Jan 1, 1982 RE28636   Start Trial
Sun Pharm Industries BACTRIM sulfamethoxazole; trimethoprim TABLET;ORAL 017377-001 Approved Prior to Jan 1, 1982 RE28636   Start Trial
Sun Pharm Industries BACTRIM DS sulfamethoxazole; trimethoprim TABLET;ORAL 017377-002 Approved Prior to Jan 1, 1982 RE28636   Start Trial
Sun Pharm Industries BACTRIM PEDIATRIC sulfamethoxazole; trimethoprim SUSPENSION;ORAL 017560-002 Approved Prior to Jan 1, 1982 RE28636   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Sun Pharm Industries Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1506211 C 2014 029 Romania   Start Trial PRODUCT NAME: COMBINATIE DE DAPAGLIFLOZIN SAU O SARE ACCEPTABILAFARMACEUTIC A ACESTUIA SI METFORMINA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTEIA; NATIONAL AUTHORISATION NUMBER: EU/1/13/900; DATE OF NATIONAL AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/900; DATE OF FIRST AUTHORISATION IN EEA: 20140116
1261586 C01261586/02 Switzerland   Start Trial PRODUCT NAME: SAXAGLIPTIN UND METFORMIN; NAT. REGISTRATION NO/DATE: SWISSMEDIC 62040 20120329
2236132 300714 Netherlands   Start Trial PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718
0443983 C300445 Netherlands   Start Trial PRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
0162036 2000C/032 Belgium   Start Trial PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329
0454511 99C0009 Belgium   Start Trial PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0502314 SPC/GB11/010 United Kingdom   Start Trial PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Mallinckrodt
Baxter
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.